Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

DRUG FOR SEPSIS TO BE TESTED FOR COVID-19

Why in news?

Sepsivac, a drug jointly developed by the Ahmedabad-based Cadilla Pharmaceuticals and the Council for Scientific and Industrial Research (CSIR), will be tested in 50 COVID-19 patients. Results from a human trial are expected in the next two months.

What is Sepsivac and can it be used for COVID-19?

  • Sepsivac was originally developed for treating sepsis by a class of pathogens called gram negative bacteria, that are known to cause life-threatening infections.
  • Given the similarities in the immune-system response in critically ill COVID-19 patients, it is theorised, the therapy could stimulate a benign response.
  • A large quantity of cytokines, chemicals signaling the presence of an infection, are produced in the early stages of the body’s response against an infection to stimulate the production of antibodies.
  • However, cytokines also cause inflammation of organs and can be counter-productive in protecting the body.
  • Keeping them in check is the goal of so-called immuno-modulators, or medicines like Sepsivac.
  • The United States and Australia are also going to start testing the efficacy of the BCG, or tuberculosis vaccine, that also employs a different strain of mycobacterium, in health care workers at the frontline of treating COVID-19 patients.

What is Sepsis?

Many coronavirus patients have died of sepsis — when the body's ...
  • Sepsis is a potentially life-threatening condition caused by the body’s response to an infection.
  • The body normally releases chemicals into the bloodstream to fight an infection.
  • Sepsis occurs when the body’s response to these chemicals is out of balance, triggering changes that can damage multiple organ systems.
Download PDF
September 2022
MTWTFSS
 1234
567891011
12131415161718
19202122232425
2627282930 
Categories